StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
BioMarin Pharma (BMRN) Posts FDA Committee Meeting Presentation on Drisapersen
November 24, 2015 10:05 AM
BioMarin Pharma (NASDAQ: BMRN) announced that the Company’s presentation from the Peripheral and Central Nervous System Drugs Advisory ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Trading Halts
Next Articles
BioMarin Pharma (BMRN) Receives Unfavorable View from FDA Panel on Kyndrisa as DMD Treatment
November 25, 2015 6:37 AM
BioMarin Pharma (BMRN) dystrophin data don't affect trial results - Bloomberg, Citing FDA Panel
November 24, 2015 5:03 PM
BioMarin Pharma's (BMRN) Drisapersen Phase 2 Issues Don't Affect Findings - FDA Panel
November 24, 2015 3:42 PM
BioMarin Posts Presentation From FDA Advisory Committee Meeting for Kyndrisa(TM) (drisapersen) for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
November 24, 2015 10:03 AM
Sarepta Therapeutics (SRPT) on Watch as BioMarin's (BMRN) Kyndrisa Adcom Set to Kickoff
November 24, 2015 7:46 AM
BioMarin Pharma (BMRN) Affirms Trading Halt Ahead of FDA Committee Review of Kyndrisa NDA
November 24, 2015 7:08 AM
